Therapie epileptischer Anfälle bei Hund und Katze

Josephine Dietzel

doi:10.1055/a-1958-0132

kleintier konkret, Table of Contents

kleintier konkret 2023; 26(01): 35-45
DOI: 10.1055/a-1958-0132

Neurologie

Therapie epileptischer Anfälle bei Hund und Katze

Josephine Dietzel

Abstract

All articles of this category

Das Auftreten epileptischer Anfälle ist einer der häufigsten neurologischen Vorstellungsgründe bei Haustieren. Die Therapie dieser Patienten kann – je nach Ursache und Krankheitsverlauf – herausfordernd sein. Dieser Artikel gibt einen Überblick über die aktuell verfügbaren therapeutischen Ansätze bei Hunden und Katzen, die an Epilepsie leiden.

Full Text

References

Literatur
1 Berendt M, Farquhar RG, Mandigers PJ. et al. International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals. BMC Vet Res 2015; 11: 1-11
2 Seppälä EH, Jokinen TS, Fukata M. et al. LGI2 truncation causes a remitting focal epilepsy in dogs. PLoS Genet 2011; 7: e1002194
3 Shih JJ, Ochoa JG. A systematic review of antiepileptic drug initiation and withdrawal. Neurologist 2009; 15: 122-131
4 Bhatti SF, De Risio L, Muñana K. et al. International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe. BMC Vet Res 2015; 11: 1-16
5 Lewis CB, Adams N. Phenobarbital. StatPearls Publishing. Im Internet (Stand: Januar 2023): https://www.ncbi.nlm.nih.gov/books/NBK532277/
6 Finnerty KE, Heller HLB, Mercier MN. et al. Evaluation of therapeutic phenobarbital concentrations and application of a classification system for seizures in cats: 30 cases (2004–2013). J Am Vet Med Assoc 2014; 244: 195-199
7 Cochrane SM, Parent JM, Black WD. et al. Pharmacokinetics of phenobarbital in the cat following multiple oral administration. Can J Vet Res 1990; 54: 309
8 Ravis W, Pedersoli W, Wike J. Pharmacokinetics of phenobarbital in dogs given multiple doses. Am J Vet Res 1989; 50: 1343-1347
9 Levitski RE, Trepanier LA. Effect of timing of blood collection on serum phenobarbital concentrations in dogs with epilepsy. J Am Vet Med Assoc 2000; 217: 200-204
10 Dayrell-Hart B, Steinberg S, VanWinkle T. et al. Hepatotoxicity of phenobarbital in dogs: 18 cases (1985–1989). J Am Vet Med Assoc 1991; 199: 1060-1066
11 Schwartz-Porsche D, Löscher W, Frey HH. Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. J Vet Pharmacol Ther 1985; 8: 113-119
12 March PA, Hillier A, Weisbrode SE. et al. Superficial necrolytic dermatitis in 11 dogs with a history of phenobarbital administration (1995–2002). J Vet Int Med 2004; 18: 65-74
13 Jacobs G, Calvert C, Kaufman A. Neutropenia and thrombocytopenia in three dogs treated with anticonvulsants. J Am Vet Med Assoc 1998; 212: 681-684
14 Kantrowitz LB, Peterson ME, Trepanier LA. et al. Serum total thyroxine, total triiodothyronine, free thyroxine, and thyrotropin concentrations in epileptic dogs treated with anticonvulsants. J Am Vet Med Assoc 1999; 214: 1804-1808
15 Vaughan-Scott T, Taylor J. Drug choice and therapeutic drug monitoring in the management of canine primary epilepsy: continuing education. J S Afr Vet Assoc 1999; 70: 172-176
16 Baird-Heinz HE, Andrea L, Pelsor FR. et al. A systematic review of the safety of potassium bromide in dogs. J Am Vet Med Assoc 2012; 240: 705-715
17 Rossmeisl JH, Inzana KD. Clinical signs, risk factors, and outcomes associated with bromide toxicosis (bromism) in dogs with idiopathic epilepsy. J Am Vet Med Assoc 2009; 234: 1425-1431
18 Dedola C, Gallucci A, Ibba F. et al. Ulcerative neutrophilic dermatitis resembling human bromoderma in a dog. J Small Anim Pract 2022; 63: 331-335
19 Boothe DM, George KL, Couch P. Disposition and clinical use of bromide in cats. J Am Vet Med Assoc 2002; 221: 1131-1135
20 Bertolani C, Hernandez J, Gomes E. et al. Bromide-associated lower airway disease: a retrospective study of seven cats. J Feline Med Surg 2012; 14: 591-597
21 Rundfeldt C, Löscher W. The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs 2014; 28: 29-43
22 Engel O, von Klopmann T, Maiolini A. et al. Imepitoin is well tolerated in healthy and epileptic cats. BMC Vet Res 2017; 13: 1-7
23 Neßler J, Rundfeldt C, Löscher W. et al. Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy. BMC Vet Res 2016; 13: 1-11
24 Gallucci A, Gagliardo T, Menchetti M. et al. Long-term efficacy of imepitoin in the treatment of naive dogs affected by idiopathic epilepsy. Vet Rec 2017; 181: 144
25 Dewey CW. Anticonvulsant therapy in dogs and cats. Vet Clin North Am Small Anim Pract 2006; 36: 1107-1127
26 Tipold A, Keefe T, Löscher W. et al. Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs. J Vet Pharmacol Ther 2015; 38: 160-168
27 Lynch BA, Lambeng N, Nocka K. et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101: 9861-9866
28 Packer R, Nye G, Porter SE. et al. Assessment into the usage of levetiracetam in a canine epilepsy clinic. BMC Vet Res 2015; 11: 1-8
29 Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6: 108-113
30 Shank RP, Gardocki JF, Streeter AJ. et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41: 3-9
31 Kiviranta AM, Laitinen-Vapaavuori O, Hielm-Björkman A. et al. Topiramate as an add-on antiepileptic drug in treating refractory canine idiopathic epilepsy. J Small Anim Pract 2013; 54: 512-520
32 Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004; 13: S5-S9
33 Dewey CW, Guiliano R, Boothe DM. et al. Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Anim Hosp Assoc 2004; 40: 285-291
34 Von Klopmann T, Rambeck B, Tipold A. Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. J Small Anim Pract 2007; 48: 134-138
35 Chung J, Hwang C, Chae J. et al. Zonisamide monotherapy for idiopathic epilepsy in dogs. N Z Vet J 2012; 60: 357-359
36 Ackermann AL, Frank LA, McEntee MF. et al. Erythema multiforme associated with zonisamide in a dog. Vet Dermatol 2015; 26: 391-392 e389
37 Schwartz M, Muñana KR, Olby NJ. Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy. J Vet Med Sci 2011; 73 (11) 1505-1508
38 Miller M, Center S, Randolph J. et al. Apparent Acute Idiosyncratic H epatic N ecrosis Associated with Z onisamide Administration in a Dog. J Vet Int Med 2011; 25: 1156-1160
39 Charalambous M, Gomes SA, Papageorgiou S. et al. Epileptic seizures versus syncope: pathophysiology and clinical approach. Veterinary Evidence 2017; 2
40 Han FY, Conboy-Schmidt L, Rybachuk G. et al. Dietary medium chain triglycerides for management of epilepsy: New data from human, dog, and rodent studies. Epilepsia 2021; 62: 1790-1806
41 Molina J, Jean-Philippe C, Conboy L. et al. Efficacy of medium chain triglyceride oil dietary supplementation in reducing seizure frequency in dogs with idiopathic epilepsy without cluster seizures: a non-blinded, prospective clinical trial. Vet Rec 2020; 187: 356-356
42 Robinson K, Platt S, Stewart G. et al. Feasibility of non-invasive vagus nerve stimulation (gammaCore VET^™) for the treatment of refractory seizure activity in dogs. Front Vet Sci 2020; 7: 569739
43 Muñana KR, Vitek SM, Tarver WB. et al. Use of vagal nerve stimulation as a treatment for refractory epilepsy in dogs. J Am Vet Med Assoc 2002; 221: 977-983
44 Shell L, Scariano R, Rishniw M. Features of stimulus-specific seizures in dogs with reflex epilepsy: 43 cases (2000–2014). J Am Vet Med Assoc 2017; 250: 75-78
45 Lowrie M, Bessant C, Harvey RJ. et al. Audiogenic reflex seizures in cats. J Feline Med Surg 2016; 18: 328-336